Key facts
- Notable investors include TEDCO, University of Maryland, LifeX Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Expora Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Expora Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Expora Therapeutics
Developer of oral bacterial extracellular vesicle disease-modifying immunotherapies designed to address gastrointestinal diseases. The company's platform integrates producer cell design, scalable low-cost manufacturing, selection of high-potency fractions, and advanced quality assurance to create consistent extracellular vesicle products, enabling patients and healthcare providers access to disease-modifying therapies for conditions such as inflammatory bowel disease and necrotizing enterocolitis.
- Sector
- Healthcare
- HQ
- College Park, MD, United States
- Founded
- 2025
- Website
- exporatx.com/
- Ownership
- Privately Held (backing)
Expora Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Expora Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Expora Therapeutics in its N-PORT filings yet. We sweep new filings monthly.